{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:15:19Z","timestamp":1777414519348,"version":"3.51.4"},"reference-count":7,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":9163,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1992,12]]},"abstract":"<jats:p>A patient suffering from schizophrenia developed diabetic keto-acidosis and NMS after treatment with neuroleptics. The combination of two uncommon complications of treatment with neuroleptics proved fatal.<\/jats:p>","DOI":"10.1192\/bjp.161.6.856","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T00:56:07Z","timestamp":1224032167000},"page":"856-858","source":"Crossref","is-referenced-by-count":13,"title":["Neuroleptic Malignant Syndrome and Diabetic Keto-acidosis"],"prefix":"10.1192","volume":"161","author":[{"given":"C.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. P.","family":"Gaete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000131125_ref1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1176\/ajp.143.12.1587","article-title":"Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients","volume":"143","author":"Addonizio","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000131125_ref7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1176\/ajp.146.6.717","article-title":"A prospective analysis of 24 episodes of neuroleptic malignant syndrome","volume":"146","author":"Rosebush","year":"1989","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000131125_ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00001504-199102000-00008"},{"key":"S0007125000131125_ref6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson","year":"1985","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000131125_ref2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.153.1.107"},{"key":"S0007125000131125_ref5","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.157.2.169"},{"key":"S0007125000131125_ref3","first-page":"403","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Baldessarini","year":"1980"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000131125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T16:14:04Z","timestamp":1558023244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000131125\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,12]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1992,12]]}},"alternative-id":["S0007125000131125"],"URL":"https:\/\/doi.org\/10.1192\/bjp.161.6.856","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,12]]}}}